Targeting Rho/MRTF regulated gene transcription in drug-resistant melanoma

被引：0
|
作者：
Misek, Sean A.
Larsen, Scott D.
Gallo, Kathleen A.
Neubig, Richard R.
机构：
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.AM2017-89
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
89
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Targeting RhoA-regulated gene transcription in drug-resistant melanoma
    Misek, Sean A.
    Gallo, Kathleen A.
    Neubig, Richard R.
    CANCER RESEARCH, 2018, 78 (13)
  • [2] Targeting drug-resistant melanoma
    Sarah Crunkhorn
    Nature Reviews Drug Discovery, 2015, 14 (2) : 94 - 94
  • [3] RHO GTPASE REGULATED GENE TRANSCRIPTION RESULTS IN AN AGGRESSIVE, UNDIFFERENTIATED MELANOMA PHENOTYPE
    Haak, Andrew J.
    Wade, Susan M.
    Bell, Jessica L.
    Larsen, Scott D.
    Verhaegen, Monique
    Lawlor, Elizabeth R.
    Neubig, Richard R.
    JOURNAL OF RECEPTORS AND SIGNAL TRANSDUCTION, 2013, 33 (03) : 189 - 190
  • [4] Targeting drug-resistant glioblastoma
    Crunkhorn, Sarah
    NATURE REVIEWS DRUG DISCOVERY, 2022, 21 (10) : 711 - 711
  • [5] Modulating myofibroblast transition in systemic sclerosis through inhibition of Rho/MRTF regulated transcription
    Haak, Andrew
    Tsou, Pei-Suen
    Fox, David
    Khanna, Dinesh
    Larsen, Scott
    Neubig, Rick
    FASEB JOURNAL, 2014, 28 (01):
  • [6] Targeting drug-resistant glioblastoma
    Sarah Crunkhorn
    Nature Reviews Drug Discovery, 2022, 21 : 711 - 711
  • [7] Targeting drug-resistant mutations in ALK
    Liu He
    Arvin C. Dar
    Nature Cancer, 2022, 3 : 659 - 661
  • [8] Molecular alterations in drug-resistant melanoma cells
    Fromme, J. E.
    Cometto, F.
    Mauch, C.
    Zigrino, P.
    EXPERIMENTAL DERMATOLOGY, 2022, 31 (02) : E102 - E103
  • [9] Metabolic rewiring in melanoma drug-resistant cells
    Bristot, Ivi Juliana
    Dias, Camila Kehl
    Chapola, Henrique
    Parsons, Richard B.
    Klamt, Fabio
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2020, 153
  • [10] Potential Novel Therapy for Drug-Resistant Melanoma
    不详
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 104 (02) : 225 - 225
12345